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Summary Previous investigators have noted that certain ovarian cancer cell lines secrete and respond to
transforming growth factor-a (TGF-a), suggesting that endogenous activation of the epidermal growth factor
(EGF) receptor through autocrine or paracrine mechanisms might contribute to the proliferative response. In
order to determine whether autocrine stimulation was partly responsible for the proliferative response in
ovarian cancer, we investigated whether the EGF receptor expressed by ovarian cancer cell lines was
constitutively activated as assessed by the presence of tyrosine phosphorylation. A specific anti-
phosphotyrosine antibody was used in conjunction with an immunoblotting technique in order to detect
EGF receptor phosphorylation in ovarian cancer cell lines in the absence and presence of exogenous EGF. The
effects of neutralising anti-EGF receptor antibody on the proliferation of ovarian cancer cell lines was also
examined. We found no evidence for constitutive tyrosine phosphorylation of the p170 EGF receptor in eight
epithelial ovarian cancer cell lines tested, although each line demonstrated inducible phosphorylation in
response to exogenous EGF. The absence of constitutive EGF receptor activation was also noted when cells
were grown under high density conditions, thus excluding a role for membrane-bound EGF or TGF-a in this
process. Media conditioned by five ovarian cancer cell lines, as well as malignant ascites obtained from 12
different ovarian cancer patients, were not capable of stimulating EGF receptor phosphorylation. Finally, the
proliferation of ovarian cancer cell lines was not significantly inhibited in the presence ofneutralising anti-EGF
receptor antibody. These data suggest that EGF receptor activation through autocrine pathways is not a major
mechanism for the growth of many ovarian cancer cell lines. Other pathways of signal transduction which
bypass the requirement for EGF receptor activation may be important in the proliferation for ovarian cancer
cells. Such EGF receptor-independent pathways may limit the effectiveness of strategies designed to inhibit
ovarian cancer cell growth through disruption of EGF receptor function.
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Epithelial ovarian cancer is a highly lethal disease which
spreads extensively throughout the abdominal cavity. Factors
which predict for poor outcome include advanced stage, older
age, high tumour grade, amplification of the c-neu proto-
oncogene and overexpression of the epidermal growth factor
(EGF) receptor (Slamon et al., 1989; Berchuck et al., 1991;
Scambia et al., 1992; Cannistra, 1993). The association
between EGF receptor expression and poor prognosis has
raised the possibility that this receptor may be involved in the
proliferative response of ovarian cancer cells in vivo through
autocrine or paracrine mechanisms. In this regard, many
ovarian cancer cell lines as well as cells from fresh ovarian
tumours respond to exogenous EGF in vitro, and some
ovarian cancer cell lines express mRNA and protein for
transforming growth factor-alpha (TGF-a), a known ligand
for the EGF receptor (Rodriguez et al., 1991; Crew et al.,
1992; Stromberg et al., 1992; Zhou and Leung, 1992;
Morishige et al., 1993). Some investigators have also shown
that neutralising anti-TGF-a antibody is capable of partly
inhibiting proliferation of certain ovarian cancer cells lines in
vitro, suggesting involvement of TGF-alpha and the EGF
receptor in an autocrine loop (Stromberg et al., 1992;
Morishige et al., 1993).
The EGF receptor is widely expressed on several types of
epithelial cells, including the normal ovarian surface
epithelium (NOSE) which gives rise to most cases of ovarian
cancer (Bast et al., 1992). This receptor is a membrane
tyrosine kinase which characteristically forms homodimers
after ligand binding to either EGF or TGF-oa (Ullrich and
Schlessinger, 1990). Homodimerisation results in stimulation
of tyrosine kinase activity and autophosphorylation of several
tyrosine moieties contained within the receptor's cytoplasmic
domain. Since tyrosine phosphorylation is critical to EGF
receptor function, detection of phosphorylated tyrosine
moieties provides an accurate assessment of this receptor's
activation state (Carpenter and Cohen et al., 1990; Ullrich
and Schlessinger, 1990).
The expression of EGF receptors by ovarian cancer cells
and the ability of these cells to respond to EGF in vitro
provides only circumstantial evidence that this signal
transduction pathway is involved in the proliferative
response. Therefore, the purpose of this study was to define
more accurately the activation status of the EGF receptor in
ovarian cancer cells by performing immunoblotting with a
specific anti-phosphotyrosine antibody. Our results demon-
strate that the EGF receptor is not constitutively activated in
many ovarian cancer cell lines, and that the proliferation of
ovarian cancer cells is not significantly inhibited in the
presence of neutralising anti-EGF receptor antibody. The
implications of these observations for ovarian cancer
pathogenesis are discussed.
Materials and methods
Reagents
Immunoblotting was performed using a previously described
murine anti-phosphotyrosine (P-Tyr) monoclonal antibody
(MAb) developed by one of us (BD). This antibody is specific
for phosphotyrosine, as demonstrated by complete elimina-
tion of immunoreactive bands with the addition of
1 mmol 1` phosphotyrosine, and it does not recognise
phosphoserine or phosphothreonine moieties (Kanakura et
al., 1990). Murine anti-EGF receptor (anti-EGF-R) antibody
(Clone Z025) used for immunoprecipitation and immuno-
blotting was purchased from Zymed (So. San Francisco, CA,
USA). Neutralising murine anti-EGF-R antibody (clone 225)
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February 1996used for inhibition of cell line proliferation was purchased
from Oncogene Science (Uniondale, NY, USA). Recombi-
nant human EGF (rhEGF) was purchased from Amgen
(Thousand Oaks, CA, USA), and rhTGF-a was purchased
from Collaborative Biomedical Products (Bedford, MA,
USA). Insulin, transferrin and cholesterol used for prepara-
tion of serum-free medium were purchased from Sigma
Chemical Company (St Louis, MO, USA).
Source of cells
Ovarian epithelial carcinoma cell lines used in this study
include CAOV-3, SKOV-3, OVCAR-3 and SW626 and were
obtained from the American Type Culture Collection
(ATCC) (Rockville, MD, USA). These cells were cultured
in Iscove's modified Dulbecco's minimal essential medium
(IMDMEM) (Gibco BRL, Grand Island, NY, USA)
supplemented with 20% fetal calf serum (FCS) (HyClone,
Logan, UT, USA). An additional cell line was developed in
our laboratory from the malignant ascites of a patient,
designated unique patient number 36 (UPN36), with
moderately well-differentiated serous papillary carcinoma of
the ovary as previously described (Cannistra et al., 1993).
This line is called UPN36T and was derived by injecting
100 x 106 ascites cells intraperitoneally into a female Swiss
Nu/Nu athymic nude mouse (Taconic, Germantown, NY,
USA) and isolating a peritoneal implant which contained
immortalised tumour cells capable of continuous in vitro
growth in 20% FCS/IMDMEM. Three other lines (UPN11,
UPN13 and UPN21) developed by us were derived from in
vitro culture of cells obtained from malignant ascites. All
ovarian cancer cell lines have been passaged for over 1 year
in IMDMEM containing 10-20% FCS without the addition
of exogenous growth factors, and they express both keratin
and vimentin as assessed by immunoperoxidase staining. The
A431 squamous cell carcinoma cell line was used as a positive
control for constitutive EGF receptor activation (Van de
Vijver et al., 1991) and was purchased from the ATCC.
Malignant ascites was obtained from ovarian cancer patients
undergoing therapeutic paracentesis for the relief of
abdominal distension. Tissue procurement was approved by
the Institutional Review Board of the Dana-Farber Cancer
Institute.
Immunoblotting
Cells were grown at subconfluent density for 18 h in either
serum-free media (SFM)(IMDMEM containing 1 jg ml-'
insulin, 5 gM transferrin, 10 jig ml-' cholesterol) or 10%
FCS before EGF stimulation. After exposure to either media
alone or EGF (10 ng ml-1) for 10 min, cells were lysed for
30 min at 4°C in lysis buffer (1% NP40, Tris 50 mm, sodium
chloride 150 mM) containing 100 mM phenylemethylsulpho-
nyl fluoride (PMSF), 0.135 trypsin-inhibitory units of
aprotinin and 40 jiM leupeptin and 5 mM sodium orthova-
nadate (Sigma). Proteins were resolved (250 jig per lane) by
one-dimensional SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) as previously described, followed by transfer
onto a 0.2 gM nitrocellulose filter (Schleicher and Schuell,
Keene, NH, USA) in transfer buffer at 0.1 amp overnight
4°C (Kanakura et al., 1990). After transfer, residual binding
sites were blocked by incubating the membrane in Tris-
buffered saline (TBS) containing 1% gelatin (BioRad
Laboratories, Melville, NY, USA) for 1 h at room
temperature (RT). The blots were then washed in TBS with
0.05% Tween 20 (TBST) and incubated for at least 4 h at RT
with the primary antibody (either anti-P-Tyr or anti-EGF
receptor MAb, 1.5-2 jig ml-' in TBST). The blots were then
washed four times in TBST, followed by incubation in a
1:2000 dilution of anti-mouse IgG conjugated to alkaline
phosphatase (Promega, Madison, WI, USA) in TBST for 2 h
at RT. After three additional washes in TBST, the blot was
placed in a buffer containing 100 mmol 1-l Tris-HCl, pH 9.5,
100 mmol m-l sodium chloride, 5 mmol 1- magnesium
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chloride, 330 jg ml-' nitro blue tetrazolium (NBT) and
150 jug ml-1 5-bromo-4-chloro-3-indolyl phosphate (BICP)
for 10-30 min. The enzymatic colour reaction was stopped
by rinsing the filters in deionised water.
Immunoprecipitation
For some experiments, immunoprecipitation of the EGF
receptor was performed before immunoblot analysis. Briefly,
7.5 x 106 cells were suspended in 1 ml lysis buffer for 30 min
at 40C. After lysis, the solubilised fraction was obtained by
centrifugation (14 000 r.p.m. x 30 min) to remove insoluble
debris, followed by preclearing with 50 ul of a 1:1 slurry of
lysis buffer and Protein A-Sepharose beads (type CL-4B,
Pharmacia, Piscataway, NJ, USA) precoated with polyclonal
rabbit anti-mouse immunoglobulin (RaM Ig, Dako). After
centrifugation, the precleared supernatant was incubated with
either an isotype-identical irrelevant antibody (DI44) or with
anti-EGF receptor antibody and rabbit anti-mouse Ig-coated
Protein A-Sepharose beads for 15 h at 40C, followed by
pelleting and washing three times in lysis buffer. The
immunoprecipitate was boiled for 5 min at 100°C in non-
reducing conditions and analysed by SDS-PAGE, followed
by protein transfer and immunoblot analysis as described
above.
Proliferation assay
The effects of EGF or anti-EGF-R antibody on the
proliferation of ovarian cancer cell lines were assessed by
measuring the cleavage of MTT (diemthylthiazol-diphenyl
tetrazolium bromide, Sigma) to formazan as previously
described (Mosmann, 1983). Briefly, cells (2.5 x 103 per well)
were added in quadruplicate to 96-well microtitre plates in a
total volume of 100 jl of IMDMEM containing 10% FCS
and allowed to incubate at 37°C for a total of 120 h. During
the last 4 h of incubation, 10 jl of MTT (5 mg ml-' in PBS)
was added, followed by the addition of 100 jl of 0.04 N
hydrochloric acid in isopropanol to dissolve the formazan.
After mixing, the optical density of each well was measured
on an ELISA plate reader at a wavelength of 590 nm.
Control cultures included incubation of cells in anti-CD44
antibody (clone 515), which is an IgGI murine monoclonal
antibody which binds to the ovarian cancer cells used in this
study but does not significantly affect their proliferation
(Cannistra et al., 1993). Specific optical density (OD) was
defined as the OD of the treatment group containing cells
minus the OD of wells containing media without cells. Data
were expressed as the stimulation index, which is a ratio of
the specific OD of the treatment group divided by the specific
OD of cells grown in the presence of control antibody (anti-
CD44 antibody).
Statistical analysis
Data are expressed as mean+standard error of the mean
(s.e.m.) where appropriate. Significance levels for comparison
of stimulation indices between treatment groups were
determined using the two-sided Student's t-test for unpaired
samples.
Results
Status of EGF receptor tyrosine phosphorylation in ovarian
cancer cell lines
In order to assess the phosphorylation status of the EGF
receptor in ovarian cancer cell lines, we performed
immunoblotting of a variety of cell lysates using a murine
anti-phosphotyrosine antibody. In pilot studies using the
CAOV-3 line, we have shown that this technique is capable
of detecting inducible phosphorylation of the p170 kDa EGF
receptor in the presence of >0.5 ng ml-1 EGF after a 10 min
exposure at 37°C, with maximum phosphorylation observedLack of EGF receptor activation
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at a dose of 10 ng ml-' EGF. The results of a typical
immunoblotting analysis for seven ovarian cancer lines
stimulated with or without 10 ng ml-' EGF (10 min at
37°C) are shown in Figure la and b. In these experiments,
cells were split the night before and grown at subconfluent
density for 18 h in SFM before immunoblotting. There was
no evidence of EGF receptor phosphorylation in any cell line
in the absence of exogenous EGF stimulation. In contrast, a
phosphotyrosine-containing molecule at 170 kDa which was
consistent with the EGF receptor (Carpenter and Cohen,
1990; Ullrich and Schlessinger, 1990) was observed for each
cell line in the presence of EGF. Other less prominent EGF-
inducible bands appear in the ranges of 66, 52 and 44/
42 kDa. The species at 66 and 52 kDa are consistent with the
known molecular masses of the SHC family of proteins
(Pelicci et al., 1992), and the p44/42 species are consistent
with the known molecular masses of MAP kinase (Wu et al.,
1991). A similar pattern of inducible EGF receptor
phosphorylation was observed for the SKOV-3 cell line
(data not shown). Results were identical for cells grown in
20% FCS/IMDMEM (instead of SFM) for 18 h before
immunoblotting. Finally, in order to ensure that the
immunoblotting technique used in this study was capable of
detecting constitutive tyrosine phosphorylation of the EGF-
R, we determined the status ofbasal EGF-R phosphorylation
in A431 cells. This cell line has been shown previously to
express activated EGF-R through autocrine secretion of
TGF-oa (Van de Vijver et al., 1991). As shown in Figure Ic, a
constitutively phosphorylated 170 kDa protein is observed in
A431 cells in the absence of EGF, although phosphorylation
is upregulated in the presence of exogenous ligand. In
comparison, there was no evidence of constitutive EGF-R
activation in CAOV-3, UPN36T or SW626 cells.
Identification ofp170 as the EGF receptor
In order to confirm that pl70 was identical to the EGF
receptor, we first treated CAOV-3 cells with or without EGF
as described, followed by immunoprecipitation of cell lysates
with an anti-EGF receptor (anti-EGF-R) antibody. Each
immunoprecipitate was divided into two equal aliquots which
were then separately resolved by SDS-PAGE for subsequent
immunoblotting with either anti-EGF-R or anti-phosphotyr-
osine antibody (Figures 2a and b). Whole cell lysates were
also loaded to serve as a control for the presence of p170.
Figure 2a shows the results of immunoblotting with the anti-
EGF-R antibody, demonstrating an EGF receptor species at
170 kDa in the whole cell lysate groups (lanes A and D) and
in the groups immunoprecipitated with anti-EGF receptor
antibody (lanes C and F). As expected, the EGF receptor is
not observed in the groups immunoprecipitated with control
antibody (anti-D144, lanes B and E). When these same
lysates are immunoblotted with anti-phosphotyrosine anti-
body as shown in Figure 2b, no reactivity is observed for
either whole cell lysates or anti-EGF receptor immunopreci-
pitates of cells treated with media alone (lanes A and C). In
contrast, there is strong expression of the p170 phosphotyr-
osine in both whole cell lysates as well as the EGF receptor
immunoprecipitates in the presence of EGF (lanes D and F).
These data demonstrate that the p170 band observed in
whole cell lysates is identical to the EGF receptor.
The effects of conditioned media and ascites on EGF receptor
phosphorylation
The majority of immunoblotting experiments performed in
this study involved ovarian cancer cell lines which were
grown for 18 h at a subconfluent density. We considered the
possibility that these conditions might result in endogenous
levels of secreted EGF or TGF-a which are insufficient to
produce EGF receptor activation, perhaps leading to falsely
negative results. In order to exclude this possibility, we first
conditioned media for 48 h in the presence of 20% FCS using
a variety of ovarian cancer cell lines at near confluence.
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Figure 1 Status of p170 tyrosine phosphorylation in ovarian
cancer cell lines. Cells were incubated in SFM for 18h and
stimulated with either SFM alone or with EGF (10ngmlF-) for
10min before lysis. Lysates were resolved by SDS-PAGE under
reducing conditions, transferred to nitrocellulose and developed
using an anti-phosphotyrosine antibody. The EGF receptor has
an expected band molecular mass of 170kDa and is not observed
in unstimulated cells. In contrast, a phosphotyrosine protein at
170kDa is observed upon EGF exposure, associated with
additional bands at 66, 52, 44 and 42kDa. Similar results were
obtained for cells incubated in 20% FCS/IMDMEM instead of
SFM. Data shown are representative results from one of three
separate experiments. (a) Immunoblot using lysates from CAOV-
3, UPN13, UPN21 and UPN36T cell lines. (b) Immunoblot using
lysates from the OVCAR-3, SW626 and UPN1 cell lines. (c)
Immunoblot using lysates from A431 cells, demonstrating
constitutive tyrosine phosphorylation of the EGF-R in the
absence of exogenous EGF (in contrast to CAOV-3, UPN36T
and SW626 cells).Medium containing 20% FCS was used to ensure maximum
growth of the culture over a more prolonged incubation
period, as cells exposed to SFM over 48 h acquire a non-
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adherent morphology associated with loss of viability. As
stated above, the use of20% FCS-containing medium by itself
was not capable ofstimulating EGF receptor phosphorylation,
suggesting that the final concentration ofEGF in this medium
was less than 0.5 ng ml-'. After 48 h, conditioned media were
then used to stimulate EGF receptor phosphorylation in
CAOV-3 cells as assessed by immunoblotting. As shown in
Figure 3, none oftheconditioned media (CM) from the fivecell
lines tested was capable of inducing EGF receptor phosphor-
ylation (10 min exposure of straight CM at 37°C before
CAOV-3 cell lysis). Similar results were obtained by using
media conditioned by the same ovarian cancer cell lines for up
to 96 h. In addition to conditioned media, we also studied
ascites samples from 12 separate ovarian cancer patients in
order to determine whether they contained physiologically
relevant levels ofeither EGF or TGF-a. As shown in Figure 4,
none of the ascites samples were capable of inducing p170
tyrosine phosphorylation in CAOV-3 cells. Co-incubation of
EGF (10 ng ml-') with 20% FCS/IMDMEM or ascites for
48 h did not diminish its ability to induce EGF receptor
phosphorylation, suggesting that growth factor degradation
was not responsible for the negative results shown in Figures 3
and 4. Finally, we considered the possibility that EGF or TGF-
c may be presented to cells in a membrane-bound form, which
would require cell-cell contact for EGF receptor stimulation.
Therefore, CAOV-3 cells were grown in 20% FCS/IMDMEM
for either 24 h (subconfluent) or 96 h (confluent) before
assessing EGF receptor phosphorylation status. As shown in
Figure 5, there was no evidence of constitutive EGF receptor
phosphorylation for either subconfluent or confluent cells. The
fact that p170 phosphorylation could be induced in confluent
cellsbyEGF(Figure 5) demonstrates thepresence offunctional
receptors at the cell surface and excludes the possibility that
receptor down-regulation is responsible for the lack of
constitutive activation at 96 h.
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Figure 2 Immunoprecipitation of the EGF receptor in CAOV-3
cells. CAOV-3 cells were treated with either media (SFM) alone
or with EGF as described previously, followed by lysis and
immunoprecipitation using a control antibody (anti-D144) or an
isotype-identical murine monoclonal antibody reactive with the
EGF receptor (anti-EGF-R). Whole cell lysates (which were not
immunoprecipitated) were also saved for SDS-PAGE analysis.
The immunoprecipitates were divided into two equal fractions
and run on two separate gels for immunoblotting with either anti-
EGF-R (a) or with anti-phosphotyrosine antibody (b). (a)
Immunoblotting with an anti-EGF-R antibody reveals a band
at 170kDa corresponding to the EGF receptor in both whole cell
lysates and anti-EGF-R immunoprecipitates (lanes A, C, D and
F). The 170kDa band was not observed in the immunoprecipi-
tates using control antibody (lanes B and E). The band at
100kDa is non-specific. (b) Immunoblotting with anti-
phosphotyrosine antibody reveals an EGF-inducible band at
170kDa in whole cell lysates (lane D) which is identified as the
EGF receptor in lane F.
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Figure 3 Effects of media conditioned by ovarian cancer cell
lines on EGF receptor tyrosine phosphorylation in CAOV-3 cells.
Conditioned media (CM) were generated by culturing a variety of
ovarian cancer cell lines in 20% FCS/IMDMEM for 48 h. CAOV-
3 cells were subsequently exposed to either SFM, EGF
(1Ongml-1), 20% FCS/IMDMEM (without conditioning) or to
CM from the indicated lines for 10min. Immunoblotting with
anti-phosphotyrosine antibody was then performed, revealing
inducible phosphorylation of p170 in only EGF-treated cells.
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Effects of anti-EGF receptor neutralising antibody on the
proliferation of ovarian cancer cell lines
These data suggest that significant levels of constitutive EGF
receptor activation are not responsible for the proliferation of
the ovarian cancer cell lines used in this study. However, we
also considered the possibility that the sensitivity of
immunoblot analysis might not be sufficient to exclude
definitively an autocrine pathway of EGF receptor activation
mediated through EGF or TGF-a secretion. In order to
determine whether external activation of the EGF receptor
might be partly responsible for the proliferation of ovarian
cancer cell lines, we incubated cells in the presence of either
EGF or anti-EGF-R antibody for 120 h, followed by
assessment of proliferation by the MTT assay as described.
As shown in Table I, the A431 squamous cell carcinoma cell
line was significantly inhibited by 10 pg ml-' of anti-EGF-R
antibody, with a stimulation index of 0.58 compared with
control antibody (anti-CD44) (P=0.001). EGF (10 ng ml-')
resulted in an inhibitory effect in A431 cells, consistent with
the known ability of relatively high concentrations of this
factor to induce apoptosis in this cell line (Gulli et al., 1995).
The inhibitory effect of EGF on A431 cells was blocked by
anti-EGF-R antibody (10 pg ml-'), thus demonstrating the
specificity of this antibody for the EGF receptor (data not
to
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Figure 4 Malignant ascitic fluid from ovarian cancer patients
does not induce EGF receptor tyrosine phosphorylation in
CAOV-3 cells. Ascites from 12 separate patients with newly
diagnosed ovarian cancer was collected in heparin (100 U ml-),
followed by centrifugation and collected of the cell-free fraction
which was used in these experiments. CAOV-3 cells were exposed
to either SFM, EGF (10ngml-') or to undiluted ascites as
indicated for 10min at 37°C. None of the ascites samples was
capable of inducing tyrosine phosphorylation of p170 in CAOV-3
cells.
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Figure 5 Effects of CAOV-3 cell density on EGF receptor
tyrosine phosphorylation. CAOV-3 cells were plated at a
subconfluent density (0.1 x 106Mml- 20% FCS/IMDMEM) and
allowed to grow for either 24 or 96h before immunoblot analysis
as described. At 24h the cells were non-confluent, whereas a
confluent monolayer was present at 96h. There was no evidence
of constitutive p170 tyrosine phosphorylation under confluent or
non-confluent conditions, although phosphorylation was inducible
by a 10min exposure to exogenous EGF (lOngml').
Table I Effects of anti-EGF receptor antibody on the proliferation
of ovarian cancer cell lines
Stimulation indexa
Cell lineb Anti-EGF-R antibodyc EGF (JOngmr')
A431 0.58 +0.03 (P = 0.001)d 0.79+0.35 (P = 0.004)
UPN36T 0.88+0.07 (P = 0.14) 1.04+0.16 (P = 0.73)
SKOV-3 0.89+0.05 (P = 0.06) 1.19 +0.06 (P =0.016)e
SW626 0.94+0.04 (P = 0.15) 1.28 +0.01 (P = 0.001)
CAOV-3 0.91 +0.06 (P = 0.16) 1.23+0.06 (P = 0.02)
OVCAR-3 0.86+0.07 (P = 0.08) 1.01 +0.12 (P = 0.18)
aProliferation was assessed by the MTT assay after 120h of
incubation as described in the text. The stimulation index is a ratio
ofthe specific optical density (OD) ofthe treatment group divided by
the specific OD ofcontrol cells grown in the presence of an irrelevant
antibody which has no effect on proliferation (anti-CD44 antibody,
lOpgMml-). bThe A431 cervical cancer cell line was used as a positive
control for the effects of anti-EGF receptor (anti-EGF-R) antibody,
which is known to block the component ofA431 proliferation due to
autocrine secretion ofTGF-a. The remaining cell lines are ovarian in
origin as described in the text. cAnti-EGF-R antibody was used at a
final concentration of 10 gml-l, since this dose was found to produce
a maximal inhibitory effect on A431 proliferation inpilotexperiments.
dData are presented as mean +standard error of the mean (s.e.m.)
stimulation index of three separate experiments. P-values were
determined by the Student's t-test for unpaired samples. eStimulation
of SKOV-3, SW626, and CAOV-3 was maximal at 10ngml-' of
exogenous EGF and was not observed at EGF concentrations below
1.0ngml-'. A similar pattemofgrowth stimulation was observed with
the use ofTGF-axbetween a range of 1.0 - 10ngml-' (data notshown).
shown). In each of five ovarian cancer lines tested, anti-
EGF-R antibody resulted in a minor inhibitory effect, with
stimulation indices ranging from 0.86 to 0.94. None of these
effects was statistically significant or reached the magnitude
of the effect observed in A431 cells. Finally, exogenous EGF
was observed to induce a statistically significant, albeit
modest, proliferative effect in three out of five lines
(SW626, CAOV-3 and SKOV-3), whereas it exerted no
effects in the UPN36T or OVCAR-3 lines (despite the ability
of EGF to induce receptor phosphorylation in these lines as
shown in Figure 1). EGF was not capable of stimulating
proliferation in any cell line at a concentration below
1.0 ng ml-'. A similar pattern of growth stimulation was
observed with the use of TGF-a between a range of 1.0-
10 ng ml-'(data not shown).
Discussion
The contribution of an autocrine or paracrine loop to the
growth of epithelial ovarian cancer cells has been difficult to
determine. Many human ovarian cancer cell lines are
responsive to EGF but are not dependent upon addition of
this growth factor for in vitro propagation (Rodriguez et al.,
1991; Crew et al., 1992; Zhou and Leung, 1992). This
observation has raised the possibility that autonomous
growth of ovarian cancer cells may be mediated through
either autocrine or paracrine secretion of EGF receptor
ligands (Morishige et al., 1993; Stromberg et al., 1992).
Alternatively, the growth ofmalignant ovarian epithelial cells
could occur through the activation of signal transduction
pathways which are independent of the EGF receptors. The
purpose of the present study was to distinguish between these
two possibilities by assessing the activation status ofthe EGF
receptor expressed by a variety of ovarian cancer cell lines.
By performing immunoblotting with a specific anti-phospho-
tyrosine antibody, we have shown that each of the eight
ovarian cancer cell lines used in this study expressed EGF
receptors, as manifested by inducible tyrosine phosphoryla-
tion of p170 after EGF exposure. However, none of these
lines demonstrated constitutive activation of the EGF
receptor in the absence of ligand. Media conditioned by
these lines for up to 48 h also failed to stimulate receptor
phosphorylation, as did malignant ascites samples from 12
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different patients. There was no evidence for receptor
activation upon cell-cell contact, excluding an important
role of membrane-bound EGF or TGF-a in this process.
Finally, anti-EGF-R antibody did not exert a significant
inhibitory effect on the proliferation of ovarian cancer cell
lines tested in this study. Taken together, these data suggest
that constitutive activation of the EGF receptor, either
through autocrine or paracrine mechanisms, is not a
common feature of many ovarian cancer cell lines.
The immunoblotting assay used in these experiments was
ideally suited to determining the role of constitutive EGF
receptor activation in ovarian cancer for several reasons. This
assay detected an inducible tyrosine phosphoprotein of
170 kDa which was shown to be specific for the EGF
receptor by immunoprecipitation. In addition, p170 was
phosphorylated by as little as 0.5 ng ml-' EGF, a concentra-
tion which typically produces an absent or low level
proliferative response in the ovarian cancer cell lines used
in this study (data not shown). It is unlikely, therefore, that
biologically significant amounts of EGF receptor ligand
present in conditioned medium or ascites would be missed
in these experiments. Although it is certainly possible that
more sensitive assays of EGF or TGF-ac measurement would
reveal the presence of these cytokines in conditioned medium
or ascites, the biological significance of these levels in the
absence of a significant effect on EGF receptor phosphoryla-
tion is difficult to determine. For instance, the use of
radioimmunoassay has revealed low level expression of
TGF-ax in the range of 0.016-0.197 ng ml-' in many
epithelial ovarian cancer cell lines, including OVCAR-3 and
SKOV-3 (Stromberg et al., 1992). The fact that we were
unable to detect growth stimulation at these TGF-a (or EGF)
concentrations suggests that this level of growth factor
secretion may not be relevant to the in vitro proliferation of
the ovarian cancer cell lines used in this study. Also,
constitutive tyrosine phosphorylation of the EGF receptor
in A431 cells was easily detected by immunoblotting (Figure
lc), suggesting that this assay should be capable of
demonstrating this phenomenon in the other cell lines used
in this study. It is important to note, however, that A431 cells
have been shown to overexpress constitutively phosphory-
lated EGF receptors dramatically (Gulli et al., 1995), raising
the possibility that the immunoblot assay used in this study
may not always be capable of detecting constitutive
phosphorylation of lower numbers of receptors typical of
ovarian cancer cell lines (Rodriguez et al., 1991). Finally, it is
known that constitutive activation of EGF receptor function
may occur through at least three distinct pathways, including
autocrine stimulation of the receptor by secreted ligands
present in the extracellular space (Di Marco et al., 1989;
Stromberg et al., 1992; Morishige et al., 1993, autocrine
stimulation by non-secreted ligands present in the cytoplas-
mic compartment (Keating and Williams, 1988), and
upregulation of function owing to EGF receptor truncation
(Khazaie et al., 1988). Since tyrosine phosphorylation is a
common feature of each of these pathways, the immunoblot-
ting technique has the additional advantage of allowing the
detection of activated EGF receptors regardless of their
mechanism of stimulation.
Although all ovarian cancer cell lines used in this study
demonstrated inducible tyrosine phosphorylation of the EGF
receptor, two of the five lines tested failed to show a
proliferative response in the presence of this growth factor
(UPN36T) and OVCAR-3). This observation is consistent
with the experience of other investigators (Rodriguez et al.,
1991), who have noted lack of EGF responsiveness despite
the presence of adequate EGF receptor surface expression.
The fact that EGF receptor activation is not always
associated with a proliferative response, coupled with the
observation that this receptor is not constitutively phos-
phorylated, suggests that other pathways of signal transduc-
tion may be important in ovarian cancer cell growth. In this
regard, it is interesting to note that Mills et al. (1988, 1990)
have characterised a soluble growth factor present in the
malignant ascites of ovarian cancer patients which is capable
of inducing ovarian cancer cell proliferation. This factor
appears to be distinct from EGF by its ability to induce
increases in intracellular calcium when added to ovarian
cancer cells in vitro (Mills et al., 1988). In addition, several
other EGF-independent pathways of signal transduction have
been identified, including activation of the c-neu proto-
oncogene, a protein which is capable of inducing malignant
transformation in vitro and which is overexpressed in over
20% of ovarian cancer specimens (Di Fiore et al., 1987;
Hudziak et al., 1987; Slamon et al., 1989). Abnormalities of
tumour-suppressor proteins such as p53, which is mutated in
over 50% of ovarian cancer specimens (Kupryjanczyk et al.,
1993; Milner et al., 1993; Teneriello et al., 1993), may also be
a critical component of disordered growth regulation in this
disease. It is possible that such EGF receptor-independent
pathways may limit the effectiveness of strategies designed to
inhibit ovarian cancer cell growth through disruption of EGF
receptor function. Although we cannot exclude a possible
contributory role of EGF receptor-mediated proliferation in
ovarian cancer pathogenesis, our data suggest that constitu-
tive activation of the EGF receptor may not be an important
component of the proliferative response in at least some cases
of ovarian cancer.
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